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Phosphoinositides have crucial roles in cellular controls, many of
which have been established through the use of small-molecule
inhibitors. Here, we describe YM201636, a potent inhibitor of the
mammalian class III phosphatidylinositol phosphate kinase
PIKfyve, which synthesizes phosphatidylinositol 3,5-bisphosphate.
Acute treatment of cells with YM201636 shows that the PIKfyve
pathway is involved in the sorting of endosomal transport, with
inhibition leading to the accumulation of a late endosomal
compartment and blockade of retroviral exit. Inhibitor specificity
is shown by the use of short interfering RNA against the target, as
well as by rescue with the drug-resistant yeast orthologue Fab1.
We concluded that the phosphatidylinositol 3,5-bisphosphate
pathway is integral to endosome formation, determining
morphology and cargo flux.
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INTRODUCTION
Phosphoinositides have crucial roles in a wide variety of cellular
processes (reviewed by Parker, 2004; Lindmo & Stenmark, 2006),
with the roles of phosphatidylinositol 3-phosphate (PtdIns3P),
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 largely explained by the use of
LY294002 (Vlahos et al, 1994) and wortmannin (Arcaro &
Wymann, 1993)—inhibitors of the PtdIns3P class of lipid kinases
(Vanhaesebroeck et al, 2001). The related lipid phosphatidyl-
inositol 3,5-bisphosphate (PtdIns(3,5)P2) has been shown to bind
to several effector proteins (Parker, 2004; Michell et al, 2006);
however, as yet there are no selective small-molecule inhibitors
that block its production and this has hampered the understanding
of the PtdIns(3,5)P2 pathway.
PIKfyve is the mammalian type III PtdInsP kinase that acts on
PtdIns3P to generate PtdIns(3,5)P2 (McEwen et al, 1999). In yeast,
inactivation of Fab1, the yeast type III PtdInsP kinase, causes a
marked enlargement of the vacuole, which fails to acidify
correctly, defects in the transport of proteins to the vacuole
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164through the multivesicular body (MVB) and failure to grow at high
temperature (Yamamoto et al, 1995; Odorizzi et al, 1998). These
effects can be explained in part by a block in retrograde transport
from the vacuole (Dove et al, 2004). Disruption of the PIKfyve
orthologues in Caenorhabditis elegans and Drosophila melanogaster
also shows a swollen endocytic compartment (Nicot et al, 2006;
Rusten et al, 2006). In mammalian cells, overexpression of a
catalytically inactive PIKfyve in COS7 or human embryonic kidney
(HEK) 293 cells causes swelling of an endocytic vacuole-like
compartment that resembles late endosomes (Ikonomov et al,
2003a), and a similar effect is shown by knockdown of PIKfyve
using short interfering RNA (siRNA; Rutherford et al, 2006).
PtdIns(3,5)P2 has also been shown to have a role in the retrieval of
cargoes to the trans-Golgi network (TGN; Rutherford et al, 2006) and
at the TGN (Ikonomov et al, 2003b), and has been implicated in
insulin-regulated IRAP/GLUT4 vesicle transport (Berwick et al, 2004).
So far, overexpression of catalytically inactive PIKfyve and
siRNA knockdown have been the only tools available to dissect
the PtdIns(3,5)P2 pathways. Although clearly informative, these
interventions have limitations owing to the gradual onset of
PtdIns(3,5)P2 depletion. siRNA treatment of cells has different
effects, depending on the extent of knockdown (Rutherford et al,
2006). Owing to the dynamic nature of many of the transport
pathways likely to be regulated by PtdIns(3,5)P2, a small-molecule
inhibitor of PIKfyve would be a valuable tool for investigating the
acute effects of blocking PtdIns(3,5)P2 synthesis and the recovery
process on release of the block. Here, we describe YM201636, a
new, potent and selective inhibitor of PIKfyve.
RESULTS AND DISCUSSION
A drug discovery programme directed at phosphoinositide 3
kinase (Hayakawa et al, 2006) identified a pyridofuropyrimidine
compound, YM201636 (Fig 1A), which was found to have potent
in vitro inhibitory activity against PIKfyve, with a half-maximal
inhibitory concentration (IC50) of 33nM (Table 1). Notably, the
yeast orthologue of PIKfyve, Fab1, was found to be insensitive to
YM201636 (IC5045mM). Under the same assay conditions, an
IC50 for PtdIns3P p110a was determined to be 3mM, almost
100-fold higher than for PIKfyve (Table 1). YM201636 did not
inhibit a type IIg PtdInsP kinase even at 10mM and inhibited a
mouse type Ia PtdInsP kinase with an IC5042mM (data not
shown). A different pyridofuropyrimidine, YM211103, showed a
significant increase in potency towards p110a (IC50 2nM), while
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Fig 1 |The specific inhibition of in vivo PtdIns(3,5)P2 production by YM201636. (A) Structures of the inhibitors. (B) PtdIns(3,5)P2 levels were
measured as described in the Methods. The data points for inhibitor-treated cells represent the percentage of radiolabel incorporated into the lipids
indicated, as a function of untreated cells (see raw data±s.d. data in Table 1). (C) NIH3T3 cells were serum-starved for 18h (0.1% donor calf serum
(DCS)) and then pretreated with vehicle ( ) or inhibitors. Cells were then stimulated with 10% DCS, as indicated. Inhibitor concentrations were as
follows: YM201636, 800nM; rapamycin, 20nM; LY294002, 10mM. Blots were probed with PW88 to detect phosphorylation of PKB 473; this serum
detects an additional nonspecific antigen at around 80kDa. (D) Serum-starved NIH3T3 cells were serum-stimulated in the presence of increasing
concentrations of YM211103, as indicated. The blot was probed for PKB 473 phosphorylation. Equal loading of samples was confirmed by probing for
total PKB (lower panel). PKB, protein kinase B; PI3,5P2, PtdIns(3,5)P2, phosphatidylinositol 3,5-bisphosphate.
Table 1|In vitro inhibitory properties of the pyridofuropyrimidine
compound YM201636 and the related YM211103
Inhibitor PIKfyve IC50 Fab1 IC50 p110a IC50
YM201636 0.033mM (0.027–0.041) 45mM 3.3mM (2.8–3.9)
YM211103 0.069mM (0.058–0.083) 410mM 0.004mM*
PIKfyve, Fab1 and p110a activities were assayed at 50mM ATP under the conditions
described in Methods. Data points were performed in triplicate; the 95% range of IC50
values are shown in parentheses.
*Data are from Workman et al (2004).
Fab1, yeast type III phosphatidylinositol kinase; IC5o, half-maximal inhibitory
concentration; PIKfyve, mammalian type III phosphatidylinositol phosphate kinase.
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165To test the in vivo effects of YM201636 on phosphoinositide
production, serum-starved NIH3T3 cells were metabolically
labelled with [32Pi]orthophosphate and serum stimulated in the
presence or absence of YM201636. At 800nM, YM201636 (see
below) decreased PtdIns(3,5)P2 production by 80% (Fig 1B;
Table 2). All other phosphoinositides identified remained largely
unaltered, although PtdIns(4,5)P2 showed a modest decrease of
around 20%. As the IC50 of YM201636 against type Ia PtdInsP
kinase is around 100-fold greater than against PIKfyve, it is likely
that this modest reduction in PtdIns(4,5)P2 is an indirect
consequence of PIKfyve inhibition. Consistent with a lack of
effect on PtdIns(3,4,5)P3, YM201636 had no influence on protein
kinase B (PKB) Ser473 phosphorylation at this concentration
(Fig 1C). By contrast, the structurally related YM211103 decreased
serum-stimulated phosphorylation of PKB (Fig 1D).
Acute treatment with YM201636 of various cell types,
including mouse embryonic fibroblasts (MEFs), Madin–Darby
canine kidney (MDCK), MCF10A, COS7 and NIH3T3 cells,
causes the formation of large vesicular structures (Fig 2;
supplementary Movie 1 online). The size and rate of formation
are time- and concentration-dependent, with an A50 of around
400nM. Withdrawal of YM201636 results in reversion of the
swollen vesicle phenotype with kinetics similar to those of
formation (Fig 2A). However, the presence of YM201636
Table 2|Effects of YM201636 treatment on phosphoinositide levels in NIH3T3 cells
PtdIns3P PtdIns4P PtdIns(3,5)P2 PtdIns(3,4)P2 PtdIns(4,5)P2
Vehicle 7,685±307 212,147±5,485 2,219±71 1,366±44 487,335±641
YM201636 7,476±484 194,539±16,732 465±52 1,319±143 393,289±16,190
PtdIns3P, phosphatidylinositol 3-phosphate.
NIH3T3 cells were labelled with [32P]Pi and stimulated with serum in the presence of vehicle (dimethyl sulphoxide) or 800nM YM201636. Cells were collected, phosphoinositides
extracted and then analysed by high-performance liquid chromatography as described in the Methods. Total radiolabel incorporation in each phosphoinositide is given as c.p.m.
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Fig 2 |Time-lapse analysis of the swollen vesicles induced by YM201636. (A) Frames from a time-lapse film of NIH3T3 cells treated with 800nM
YM201636 (þYM201636). At 120min, the cells were washed free of YM201636 and placed in fresh medium ( YM201636). The boxed region in panels
4–6 highlights a cell undergoing division.
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166(800nM) does not inhibit cell division (Fig 2, boxed dividing cell).
Growth curves for NIH3T3 cells over 7 days showed modest
(25%) inhibitory effects (data not shown), which would indicate
that other essential phosphoinositide pathways, for example,
PtdIns(4,5)P2 synthesis, are not affected significantly.
Transfection of any of four selected siRNA sequences targeting
PIKfyve caused morphological changes similar to YM201636
treatment. Transfection of the most potent into NIH3T3 cells
caused extensive vesicle swelling in 25% of cells (Fig 3A),
consistent with the transfection efficiency and confirming previous
observations (Rutherford et al, 2006).
To confirm further that PIKfyve is a target of YM201636, we
expressed the YM201636-insensitive yeast type III PtdInsP kinase
Fab1 in cells treated with the inhibitor. Fab1 is able to partly rescue
the effects of YM201636, with a 50–60% reduction in the number
and a reduction in the size of swollen vesicles induced (Fig 3B).
Together, these data show that YM201636 induces the vesiculation
phenotype by affecting PIKfyve and PtdIns(3,5)P2 production.
To analyse the origins and nature of the vesicle compartments
expanded by acute inhibition of PIKfyve, we examined the
localization of several compartmental markers. Not one of the
Golgi markers (GM130 (Nakamura et al, 1995) and p230 (Erlich
et al, 1996; Gleeson et al, 1996)), endoplasmic reticulum markers
(p62 (Davis & Blobel, 1986), p115 (Barroso et al, 1995;
Sapperstein et al, 1995), calnexin (Wada et al, 1991)) or the
lysosomal marker LAMP1 was found on the swollen vesicle
membrane or intralumenal vesicle (data not shown; supplemen-
tary Fig S1 online), indicating that Golgi, endoplasmic reticulum
and lysosomes do not contribute directly to the dilated vesicles.
Staining for the endosomal marker EEA1 (early endosomal antigen 1)
showed a typical punctate cytoplasmic distribution (supplementary
Fig S2 online), which, after treatment with 800nM YM201636,
became concentrated on the surface of a subset of enlarged
vesicular structures and on some lumenal vesicles (Fig 4A).
Generally, the distribution of EEA1 was enriched on smaller
vesicles, covering their entire surface, and was mostly absent from
larger vesicles (45mm in diameter). Transfection of a green
fluorescent protein (GFP)-tagged tandem FYVEHrs (Gaullier et al,
1998) was used to track PtdIns3P on cellular membranes (Fig 4B).
Co-staining for EEA1 showed localization to areas of PtdIns3P
concentration and also that EEA1 was concentrated in subdomains
on the surface of the swollen vesicles. Vesicles were found to be
sheathed in actin filaments and to require an intact microtubule
network for formation (supplementary Fig S3 online). Filming cells
expressing GFP-Rab5 (supplementary Movie 2 online) provided
clear evidence that Rab5-positive compartments contributed to
the accumulating swollen vesicle phenotype. However, the
heterogeneous nature of the swollen vesicles indicates that they
are probably derived from multiple compartments, and electron
microscopic analysis supported this (supplementary Fig S4 online).
Expression of the PIKfyveK1831E kinase-dead mutant or
depletion of PIKfyve by siRNA indicates that PIKfyve regulates
cation-independent mannose 6-phosphate receptor (CI-MPR)
recycling from the late endosome (Ikonomov et al, 2003a;
Rutherford et al, 2006). NIH3T3 cells stained for CI-MPR showed
a defined polarized perinuclear distribution (supplementary
Fig S5A online). Treatment with 800nM YM201636 did not
substantially alter this, except that a relatively small number of
enlarged vesicles in the same region stained positive for CI-MPR
(Fig 4C). Most of the enlarged vesicles towards the periphery of the
cell and in other areas of the perinuclear region were negative for
CI-MPR, indicating either that they had lost CI-MPR or that they
were derived from endocytic compartments not directly on the
CI-MPR recycling pathway. Colocalization of CI-MPR and
GFP-tandem-FYVEHrs domain was seen in the defined perinuclear
region, but a clear separation existed in other perinuclear areas
(Fig 4D). Thus, our data indicate that the PIKfyve-dependent

























































Fig 3 |PIKfyve is the cellular target of YM201636. (A) Phase-contrast images of NIH3T3 cells transfected with siRNA to PIKfyve; the insets show
magnified views. A 25% portion of the cells showed this vesiculation phenotype, which is consistent with the transfection efficiency; no such behaviour
was observed with non-PIKfyve-directed siRNA. The siRNA used is shown above the images. (B) pEGFP or GFP-Fab1 fusion proteins were expressed
in NIH3T3 cells and the cells were treated for 2h with 800nM YM201636. The data are from three independent transfections. EGFP, enhanced GFP;
GFP, green fluorescent protein; PIKfyve, mammalian type III phosphatidylinositol phosphate kinase; siRNA, short interfering RNA.
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167previous, chronic inhibition studies (Ikonomov et al, 2003a;
Rutherford et al, 2006) might represent a terminal phenotype.
On exposure to Lucifer yellow and either pre- or post-treatment
with YM201636, lumenal vesicles could be seen to retain the
yellow stain; the bulk of the vesicles did not fluoresce (Fig 5A).
Consistently, the distribution of epidermal growth factor (EGF)
receptors in both COS7 and NIH3T3 cells after EGF stimulation in
the presence of 800nM YM201636 showed not only that
endocytic vesicles are found in the lumen of the swollen vesicles,
but also that the outer membrane of a subpopulation of swollen
vesicles becomes highly enriched for EGF receptors (Fig 5B). The
data suggest that both invagination and engulfment events were
still occurring in the presence of the inhibitor; to account for the
large increase in the surface area of the swollen vesicles, fusion
events must also have been occurring (see also Rab5 in the
supplementary Movie 2 online).
It is known from yeast deficient in Fab1 that the aberrant
enlarged vacuole formed is poorly acidified (Yamamoto et al,
1995). By using the pH-sensitive dye lysotracker (Invitrogen,
Paisley, UK), it was found that the swollen vesicles in NIH3T3
cells treated with YM201636 were also poorly acidified (Fig 5C).
However, surprisingly, some of the intralumenal vesicles that
could be seen in the phase-contrast image were strongly

















Fig 4 |Endosomal markers localize to the swollen vesicles. (A) Localization of EEA1 in NIH3T3 cells treated with 800nM YM201636 for 2h. The phase
image is merged with the fluorescent image in the bottom panel. (B) Localization of EEA1 and GFP-tandem-FYVEHrs domain (FYVEHrs) in NIH3T3
cells treated with YM201636 for 2h. (C) Localization of the cation-independent mannose-6-phosphate receptor (Cl-MPR) in NIH3T3 cells treated with
800nM YM201636 for 2h. (D) Localization of Cl-MPR and transfected GFP-tandem-FYVEHrs domain in NIH3T3 cells treated with 800nM YM201636
for 2h. EEA1, early endosomal antigen 1; GFP, green fluorescent protein.
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168vesicles acidify post-entry or that existing acidified vesicles are
engulfed by the swollen vesicles. This autophagic behaviour is
characteristic of the response to amino-acid deprivation. To assess
autophagic activity, the GFP-tagged autophagosome marker LC3
(Kabeya et al, 2000) was transfected into NIH3T3 cells. When
these cells were treated with YM201636, it was apparent that most
of LC3 accumulated inside the enlarged vesicles (supplementary
Fig S7 online). This suggests that there is a degree of constitutive
autophagy under these conditions and that the normal autophagic
pathway is aberrant when PIKfyve is inhibited. Autophagic protein
breakdown was indeed reduced in YM201636-treated cells
(supplementary Fig S7 online), although whether this is a direct
or indirect effect of PIKfyve inhibition remains unclear.
It has been shown that retroviruses bud from the cell by using
the ESCRT (endosomal sorting complex required for transport)
machinery that is normally used in protein sorting through the
MVB (Martin-Serrano et al, 2003; Pornillos et al, 2003; Sherer
et al, 2003), and that knockdown of PIKfyve by siRNA inhibits
viral proliferation (Murray et al, 2005). We used TEGH human
fibrosarcoma line (TEFLY Mo) producing ecotopic retrovirus
containing pBabe-puro to test whether YM201636 has any effects
on viral budding. Remarkably, treatment with 800nM YM201636
reduced virus released into the medium by 80% (supplementary
Fig S8 online). In control cells, the residual virus particles
associated with cells were typically present in intercellular spaces.
By contrast, in YM201636-treated cells, there was a substantial
reduction in the number of virus particles associated with cellular
sections, and where visible these were almost exclusively present
in vacuolated structures. In two fields from YM201636-treated
cells, a viral particle was observed connected to vacuolated
membranes by an electron-dense material, probably unsevered
membrane. The direct titre and ultrastructural analysis indicate
that inhibition of PIKfyve blocks the formation and release of
mature viral particles, as cellular viral particle accumulation was
not observed in the context of reduced viral release.
In conclusion, YM201636 is a selective inhibitor of PIKfyve and
PtdIns(3,5)P2 production in cells, acutely inducing swollen vesicles
that derive in part from endosomal material and also from
aberrant autophagosomal processes. It is evident that both typical,
microtubule-dependent endosome fusion events and autophagic
processes—although atypical—can be maintained despite the loss
of PtdIns(3,5)P2 production. The accumulation of EGF receptors on
the limiting membrane of the swollen vesicles is indicative of
incorrect cargo sorting, similar to the block observed in the loss
of function of Fab1 in yeast (Odorizzi et al, 1998) and in
D. melanogaster (Rusten et al, 2006). The presence of some EGF
receptors in the lumen is likely to reflect autophagic activity, as
evidenced by the presence of Lucifer yellow-positive lumenal
vesicles. However, whether the invagination is blocked as a
primary event or secondary to the recycling of essential proteins, for
example, ESCRT complex components, remains to be established.
METHODS
Routine methods. Plasmid constructs, cell labelling and western
blot protocols were as described previously (supplementary informa-
tion online). Confocal, electron and video microscopic examinations
were carried out as described previously (supplementary information
online). siRNA knockdown and the protein turnover protocols are
documented in the supplementary information online. Compounds
were synthesized as described previously (Hayakawa et al, 2007).
In vitro lipid kinase assays. In vitro lipid kinase assays and lipid
analysis were carried out as described previously (Cooke et al,
1998). IC50 values were determined by using Graphpad Prism and
errors are given as ±95% confidence limit. PtdIns3P assays were
carried out as for GST-Fab1 and GST-PIKfyve assays except that
100mM PtdIns was used as a substrate.
In vivo measurement of phosphoinositide. In vivo levels of
phosphoinositides were measured as described previously
(Dove et al, 1997). Briefly, subconfluent 6cm Petri dishes of





EGF receptor Lysotracker dye AB C
Fig 5 |Endosomal and lysosomal tracers are localized to the swollen vesicles. (A) NIH3T3 cells were incubated with 2mg/ml Lucifer yellow for 30min
and then treated for 2h with 800nM YM201636. (B) Serum-starved NIH3T3 cells (20h, 0.1% FCS) were treated with 800nM YM201636 for 2h and
then stimulated with 10nM EGF for 60min. The EGF receptor was then stained with anti-EGF receptor and anti-mouse-cy3. (C) NIH3T3 cells were
treated for 3h with 800nM YM201636; for the final 0.5h, Lysotracker Red DND-99 was added to the medium at 100nM. Lysotracker is acidotropic
and accumulates in acidified organelles. EGF, epidermal growth factor.
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169(Sigma-Aldrich, Haverhill, UK), 140mM NaCl, 5mM KCl, 2.8mM
NaHCO3, 1.5mM CaCl2, 1mM MgCl2, 0.06mM MgSO4, 5.6mM
glucose, 0.1% (w/v) FAF BSA; pH 7.4 at 371C) and incubated with
0.3mCi per dish of [32P]Pi (GE Healthcare, Amersham, UK) for
1.5h. The cells were washed once in HBBSS and challenged with
10% serum in HBBSS in the presence or absence of YM201636.
After 10min, the medium was removed from the cells and the
cells were killed with 0.5ml of ice-cold 1M HCl. Phosphoinositides
were extracted and analysed by using high-performance liquid
chromatography as described previously (Dove et al, 1997).
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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